Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31150392 | 1.00 | THRB (0.36) | THRBHPGDHSD17B10TSHRCASP1 | |
| SCHEMBL30008043 | 0.82 | THRB (0.36) | THRBHPGDHSD17B10TSHRCASP1 | |
| SCHEMBL25027697 | 0.82 | THRB (0.36) | THRBHPGDHSD17B10TSHRCASP1 | |
| SCHEMBL11589756 | 0.80 | HSD17B1 (0.39) | HSD17B1HSD17B2ALDH1A1CA12CA1 | |
| SCHEMBL31150397 | 0.80 | HSD17B1 (0.39) | HSD17B1HSD17B2ALDH1A1CA12CA1 | |
| SCHEMBL9027960 | 0.78 | HSD17B10 (0.38) | THRBHPGDHSD17B10TSHRCASP1 | |
| SCHEMBL8525834 | 0.78 | GAA (0.35) | CYP3A4ALDH1A1CA12CA1CA2 | |
| SCHEMBL10616500 | 0.78 | GAA (0.35) | CYP3A4ALDH1A1CA12CA1CA2 | |
| SCHEMBL78211 | 0.74 | CA1 (0.43) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL8870542 | 0.73 | ALDH1A1 (0.36) | HSD17B1HSD17B2ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2020261156-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261156-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | THRB 516/4885HPGD 3978/4885HSD17B10 3960/4885 |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | THRB 516/4885HPGD 3978/4885HSD17B10 3960/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | THRB 516/4885HPGD 3978/4885HSD17B10 3960/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | THRB 516/4885HPGD 3978/4885HSD17B10 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.